Adaptive Phase I clinical trial design using Markov models for conditional probability of toxicity

References

• Babb, J., Rogatko, A., Zacks, S. (1998). Cancer phase I clinical trials: Efficient dose escalation with overdose control. Statistics in Medicine 17:1103–1120.
   PubMed Web of Science ®Google Scholar
• Cheung, Y., Elkind, M. (2010). Stochastic approximation with virtual observations for dose-finding on discrete levels. Biometrika 97:109–121.
   PubMed Web of Science ®Google Scholar
• Doussau, A., Thiébaut, R., Paoletti, X. (2013). Dose-finding design using mixed-effect proportional odds model for longitudinal graded toxicity data in phase I oncology clinical trials. Statistics in Medicine 32:5430–5447.
   PubMed Web of Science ®Google Scholar
• Lee, S., Cheng, B., Cheung, Y. (2011). Continual reassessment method with multiple toxicity constraints. Biostatistics 12:386–98.
   PubMed Web of Science ®Google Scholar
• Lee, S., Cheung, Y. (2009). Model calibration in the continual reassessment method. Clinical Trials 6:227–238.
   PubMed Web of Science ®Google Scholar
• Legedza, A., Ibrahim, J. (2000). Longitudinal design for phase I clinical trials using the continual reassessment method. Controlled Clinical Trials 21:574–588.
   PubMedGoogle Scholar
• O’Quigley, J., Chevret, S. (1991). Methods for dose finding studies in cancer clinical trials: a review and results of a Monte Carlo study. Statistics in Medicine 10:1647–64.
   PubMed Web of Science ®Google Scholar
• O’Quigley, J., Pepe, M., Fisher, L. (1990). Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46:33–48.
   PubMed Web of Science ®Google Scholar
• Paoletti, X., Le Tourneau, C., Verweij, J., Siu, L. L., Seymour, L., Postel-Vinay, S., Collette, L., Rizzo, E., Ivy, P., Olmos, D., Massard, C., Lacombe, D., Kaye, S. B., Soria, J.-C. (2014). Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey. European Journal of Cancer 50:2050–2056.
   PubMed Web of Science ®Google Scholar
• Plummer, M. (2011). rjags: Bayesian Graphical Models Using MCMC. http://CRAN.R-project.org/package=rjags.
   Google Scholar
• Postel-Vinay, S., Collette, L., Paoletti, X., Rizzo, E., Massard, C., Olmos, D., Fowst, C., Levy, B., Mancini, P., Lacombe, D., Ivy, P., Seymour, L., Tourneau, C. L., Siu, L. L., Kaye, S. B., Verweij, J., Soria, J.-C. (2014). Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – dose-limiting toxicity and toxicity assessment recommendation group for early trials of targeted therapies, an European organisation for research and treatment of cancer-led study. European Journal of Cancer 50:2040–2049.
   PubMed Web of Science ®Google Scholar
• R Development Core Team. (2011). R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing.
   Google Scholar
• Robert, C., Casella, G. (1999). Monte Carlo Statistical Methods. New York: Springer.
   Google Scholar
• Simon, R., Freidlin, B., Rubinstein, L., Arbuck, S., Collins, J., Christian, M. (1997). Accelerated titration designs for phase I clinical trials in oncology. Journal of the National Cancer Institute 89:1138–47.
   PubMed Web of Science ®Google Scholar
• Storer, B. (1989). Design and analysis of phase I clinical trials. Biometrics 45:925–937.
   PubMed Web of Science ®Google Scholar
• Thall, P., Lee, S. (2003). Practical model-based dose-finding in phase I clinical trials: Methods based on toxicity. International Journal of Gynecological Cancer 13:251–61.
   PubMed Web of Science ®Google Scholar
• Whitehead, J., Patterson, S., Webber, D., Francis, S., Zhou, Y. (2001). Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics 2:47–61.
   PubMedGoogle Scholar
• Whitehead, J., Zhou, Y., Mander, A., Ritchie, S., Sabin, A., Wright, A. (2006). An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers. Statistics in Medicine 25:433–445.
   PubMed Web of Science ®Google Scholar
• Zhang, J., Braun, T. (2013). A phase I Bayesian adaptive design to simultaneously optimize dose and schedule assignments both between and within patients. Journal of the American Statistical Association 108:892–901.
   Web of Science ®Google Scholar